#ASCO22: Playing catch-up with Lumakras: Mirati touts CNS-specific activity that analysts think pad the case for approval
CHICAGO — Mirati Therapeutics is pulling out all the stops to beef up its case for adagrasib, as the biotech could be 18 months behind Amgen’s Lumakras to market if approved by the FDA in December.
The biotech said its drug led to six objective intracranial responses in 19 evaluable patients with non-small cell lung cancer who have active and untreated CNS metastases. That 32% figure is similar to the 33% intracranial ORR previously reported in patients who have been treated for the CNS metastases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.